Limited relevance of the CHEK2 gene in hereditary breast cancer

International Journal of Cancer

Volumn 110, Issue 3, 2004, Pages 320-325

  Dufault, Michael R ^a   Betz, Beate ^a   Wappenschmidt, Barbara ^a   Hofmann, Wera ^b   Bandick, Katrin ^a   Golla, Astrid ^c   Pietschmann, Andrea ^b   Nestle Krämling, Caroline ^a   Rhiem, Kerstin ^a   Hüttner, Christine ^d   Von Lindern, Celia ^a   Dall, Peter ^a   Kiechle, Marion ^a,e   Untch, Michael ^f   Jonat, Walter ^a   Meindl, Alfons ^a,e,f   Scherneck, Siegfried ^b   Niederacher, Dieter ^a   Schmutzler, Rita K ^a   Arnold, Norbert ^a  

^a Department of Medical Genetics ^*  (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c Institute for Epidemiology   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f UNIVERSITY OF MUNICH   (Germany)

Author keywords

BRCA1; BRCA2; Breast cancer; CHEK2; Mutation analysis

Indexed keywords

BRCA2 PROTEIN; CHECKPOINT KINASE 2;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; EXON; FEMALE; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; GENETIC CODE; GERMANY; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MISSENSE MUTATION; ONCOGENE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZATION;

BREAST NEOPLASMS; EXONS; FEMALE; GENE DELETION; GENES, BRCA1; GENES, BRCA2; HUMANS; MALE; MUTATION; MUTATION, MISSENSE; OVARIAN NEOPLASMS; PEDIGREE; POLYMERASE CHAIN REACTION; PROTEIN-SERINE-THREONINE KINASES;

EID: 2442476240     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20073     Document Type: Article

References (21)

1. Bartek J, Falck J, Lukas J. CHK2 kinase: a busy messenger. Nat Rev Mol Cell Biol 2001;2:877-86.
2. Miller CW, Ikezoe T, Krug U, Hofmann WK, Tavor S, Vegesna V, Tsukasaki K, Takeuchi S, Koeffler HP. Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung and ovarian tumors. Genes Chromosomes Cancer 2002;33:17-21.
3. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999;286:2528-31.
4. CHEK2 Breast Cancer Consortium. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002;31:55-9.
5. Allinen M, Huusko P, Mantyniemi S, Launonen V, Winqvist R. Mutation analysis of the CHK2 gene in families with hereditary breast cancer. Br J Cancer 2002;85:209-12.
6. Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomaki K, Heikkila P, Holli K, Blomqvist C, et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002;71:432-8.
7. Offit K, Pierce H, Kirchhoff T, Kolachana P, Rapaport B, Gregersen P, Johnson S, Yossepowitch O, Huang H, Satagopan J, Robson M, Scheuer L, et al. Frequency of CHEK2*1100delC in New York breast cancer cases and controls. BMC Med Genet 2003;4:1-4.
8. Sodha N, Bullock S, Taylor R, Mitchell G, Guertl-Lackner B, Williams RD, Bevan S, Bishop K, McGuire S, Houlston RS, Eeles RA. CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours. Br J Cancer 2002;87:1445-8.
9. Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK, Qian C, Marks AF, Slager SL, Peterson BJ, Smith DI, Cheville JC, et al. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 2003;72:270-80.
10. German Consortium for Hereditary Breast and Ovarian Cancer. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer 2002:97:472-80.
11. Sodha N, Houlston RS, Williams R, Yuille MA, Mangion J, Eeles RA. A robust method for detecting CHK2/RAD53 mutations in genomic DNA. Hum Mutat 2002;19:173-7.
12. Kilpivaara O, Vahteristo P, Syrjähkoski K, Eerola H, Bartkova J, Aittomäki K, Heikkilä P, Bartek J, Holli K, Blomqvist C, Kallioniemi O-P, Nevanlinna H. A CHEK2 variant with increased breast cancer risk. Am J Hum Genet 2002;71(Suppl):372.
13. Walsh T, Young T-L, Snook S, Newman B, Milikan B, N.Y.B.C.S. Consortium, Laing K, Green J, King M-C. Analysis of CHEK2 1100delC in North American breast cancer families and population based breast cancer series. Am J Hum Genet 2002;71(Suppl):90.
14. Schutte M, Seal S, Barfoot R, Meijers-Heijboer H, Wasielewski M, Evans DG, Eccles D, Meijers C, Lohman F, Klijn J, van den Ouweland A, Futreal PA, et al. Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am J Hum Genet 2003;72:1023-8.
15. Nevanlinna H. CHEK2 gene. The Breast Cancer Linkage Consortium (BCLC) and the International Collaborative Group on Familial Breast and Ovarian Cancer (ICG-FBOC) 14th General Meeting at the Centro National de Investigaciones Oncologica (CNIO), Madrid, Spain, 2-4 June 2003:46.
16. Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001;410:842-7.
17. Falck J, Lukas C, Protopopova M, Lukas J, Selivanova C, Bartek J. Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway. Oncogene 2001;20:5503-10.
18. Li J, Williams BL, Haire LF, Goldberg M, Wilker E, Durocher D, Yaffe MB, Jackson SP, Smerdon SJ. Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2. Mol Cell 2002;9:1045-54.
19. Osorio A, de la Hoya M, Rodriguez-Lopez R, Martinez-Ramirez A, Cazorla A, Granizo JJ, Esteller M, Rivas C, Caldes T, Benitez J. Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer. Int J Cancer 2002;10:305-9.
20. Pharoah PDP, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BAJ. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002;31:33-6.
21. Antoniou AC, Pharoah PDP, McMullan G, Day NE, Ponder BAJ, Easton D. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 2001;21:1-18.